No Data
No Data
Vor Biopharma's Chief Medical Officer Resigns
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
JMP Securities Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $6
Optimistic Buy Rating for Vor Biopharma Amid Promising Clinical Developments and Stable Financial Position
Wedbush Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $7
Express News | Oppenheimer Reiterates Outperform on Vor Biopharma, Maintains $8 Price Target